Compare Cytokinetics Inc (CYTK) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Global X Lithium & Battery Tech ETF trades at $69.02 (market cap $1.49B). The key difference: Cytokinetics Inc is far larger — about 5.7× Global X Lithium & Battery Tech ETF's market cap, and Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Global X Lithium & Battery Tech ETF for 56 Days on average.
| CYTK | LIT | |
|---|---|---|
Market Cap | $8.50B | $1.49B |
Volume | 2,395,556 | 67,221 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $87.26 | $91.62 |
52-Week Low | $54.76 | $53.92 |
Typical Hold Time | 19 Days | 56 Days |
Enterprise Value | $8.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
LIT trades at $69.51, down 2.2% today amid mixed technical signals with a bullish overall rating but bearish moving averages and oscillators. The ETF's recent performance reflects volatility in lithium markets, with short interest dropping 53.1% in September. Key technical levels show support at $70 and resistance at $72. Recent news highlights ongoing EV sector growth with China targeting 30% NEV fleet by 2030, providing long-term tailwinds.
LIT offers exposure to the expanding battery technology sector with catalysts from EV adoption and energy storage demand. However, risks include lithium price volatility and Chinese export controls. The ETF's momentum is supported by semiconductor and AI-driven battery demand, though current technical indicators suggest near-term consolidation may precede further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
